



Related Publications

Safety first

Kim M. (2015) Naturally occurring reoviruses for human cancer therapy. *BMB Rep.* 48:454-460

Kim M. (2015) Replicating poxviruses for human cancer therapy. *J Microbiol.* 53:209-218.

Kim M, Madlambayan GJ, Rahman MM, Smallwood SE, Meacham AM, Hosaka K, Scott EW, Cogle CR*, McFadden G* (2009). Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells. *Leukemia.* 12:2313-7

Effective treatments

Park J, **Kim M.** (2016) Replicating viruses for gynecologic cancer therapy. *Eur J Gynaecol Oncol.* 37: 295-304.

Kim M, Rahman MM, Cogle CR, McFadden G.(2015) Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease. *Biochem Biophys Res Commun.* 462:283-287.

Kim M, Williamson CT, Prudhomme J, Bebb DG, Riabowol K, Lee PW, Lees-Miller SP, Mori Y, Rahman MM, McFadden G, Johnston RN.(2010) The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status. *Oncogene.* 29:3990-3996

Lasting cures

Kim M, Egan C, Alain T, Urbanski S, Lee P, Forsyth P, Johnston RN. (2007) Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells. *Oncogene* 26:4124-34.